Labcorp Expects 2024 Adjusted EPS Of $14.30-$14.70 Versus Prior Guidance Of $14.30-$14.90 And Consensus Of $14.56
|
|
| Previous |
| Updated |
| Results |
| 2024 Guidance |
| 2024 Guidance |
|
|
|
|
|
|
|
|
| 2023 |
| Low | High |
| Low | High |
| Revenue |
|
|
|
|
|
|
|
| Labcorp Enterprise (1)(2) | $12.2 |
| 6.4 % | 7.5 % |
| 6.6 % | 7.3 % |
| Diagnostics Laboratories | $9.4 |
| 6.9 % | 7.9 % |
| 7.2 % | 7.8 % |
| Biopharma Laboratory Services (3) | $2.8 |
| 3.7 % | 5.0 % |
| 4.7 % | 5.6 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adjusted EPS | $13.56 |
| $14.30 | $14.90 |
| $14.30 | $14.70 |
|
|
|
|
|
|
|
|
| Free Cash Flow from Cont. Ops(4) | $0.89 |
| $0.85 | $1.00 |
| $0.85 | $0.98 |
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。